Stock Events

Stock Events

Bitwise MARA Option Income Strategy 

$14.59
976
+$0.12+0.83% Friday 19:59
-$0.23-1.58%Friday 23:29After hours

Statistics

Day High
14.59
Day Low
14.48
52W High
42.32
52W Low
11.99
Volume
2,976
Avg. Volume
3,800
Mkt Cap
1.07B
P/E Ratio
-
Dividend Yield
9.83%
Dividend
1.43

Upcoming

Dividends

9.83%Dividend Yield
Sep 26
$0.12
Aug 26
$0.12
Jun 26
$0.12
May 26
$0.17
Apr 26
$0.15
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
-11.02%

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.57
-0.49
-0.4
-0.32
Expected EPS
-0.428925
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-103.69MNet Income

Analyst Ratings

74.71Average Price Target
The highest estimate is 80.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing directly with Enliven Therapeutics' cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, directly competing with Enliven Therapeutics.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad range of oncology products that compete in the same market as Enliven Therapeutics' cancer treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong focus on oncology, with a portfolio that competes with Enliven Therapeutics in developing cancer therapies.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on innovative healthcare solutions, including oncology, where it competes with Enliven Therapeutics in the cancer treatment space.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, is a leader in oncology, directly competing with Enliven Therapeutics in cancer drug development.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is known for its strong presence in the oncology market, offering competitive therapies to those developed by Enliven Therapeutics.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies including oncology, which puts it in direct competition with Enliven Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in the discovery and development of pharmaceutical products for the treatment of cancer, among other diseases, competing with Enliven Therapeutics.

Regions

About

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Show more...
CEO
Richard A. Fair
Employees
67
Country
United States
ISIN
US0917487078

Listings

BOATS
BOATS
ELVN.BOATS
XNAS
US
ELVN

0 Comments

Share your thoughts

FAQ

What is Bitwise MARA Option Income Strategy stock price today?▼
The current price of IMRA is $14.59 USD — it has increased by +0.83% in the past 24 hours. Watch Bitwise MARA Option Income Strategy stock price performance more closely on the chart.
What is Bitwise MARA Option Income Strategy stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on ARCX exchange Bitwise MARA Option Income Strategy stocks are traded under the ticker IMRA.
Is Bitwise MARA Option Income Strategy stock price growing?▼
IMRA stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Bitwise MARA Option Income Strategy has showed a -58.82% decrease.
What is Bitwise MARA Option Income Strategy market cap?▼
Today Bitwise MARA Option Income Strategy has the market capitalization of 1.07B
When is the next Bitwise MARA Option Income Strategy earnings date?▼
Bitwise MARA Option Income Strategy is going to release the next earnings report on November 18, 2026.
What were Bitwise MARA Option Income Strategy earnings last quarter?▼
IMRA earnings for the last quarter are -0.49 USD per share, whereas the estimation was -0.39 USD resulting in a -26.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bitwise MARA Option Income Strategy revenue for the last year?▼
Bitwise MARA Option Income Strategy revenue for the last year amounts to 0 USD.
What is Bitwise MARA Option Income Strategy net income for the last year?▼
IMRA net income for the last year is -103.69M USD.
Does Bitwise MARA Option Income Strategy pay dividends?▼
Yes, IMRA dividends are paid monthly. The last dividend per share was 0.12 USD. As of today, Dividend Yield (FWD)% is 9.83%.
How many employees does Bitwise MARA Option Income Strategy have?▼
As of September 06, 2026, the company has 67 employees.
In which sector is Bitwise MARA Option Income Strategy located?▼
Bitwise MARA Option Income Strategy operates in the Health & Wellness sector.
When did Bitwise MARA Option Income Strategy complete a stock split?▼
The last stock split for Bitwise MARA Option Income Strategy was on February 24, 2023 with a ratio of 1:4.
Where is Bitwise MARA Option Income Strategy headquartered?▼
Bitwise MARA Option Income Strategy is headquartered in BURLINGAME, United States.